Overview

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Status:
Completed
Trial end date:
2018-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Medivation, Inc.
Pfizer
Collaborators:
Astellas Pharma Inc
Medivation is now a wholly owned subsidiary of Pfizer Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Treatments:
Docetaxel